Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29795174 | 1.00 | ENPP2 (0.55) | ENPP2FFAR1NPC1RAB9AMAOA | |
| SCHEMBL257853 | 0.92 | ENPP2 (0.50) | ENPP2FFAR1MAOAMAOBSIRT2 | |
| SCHEMBL12030691 | 0.90 | ENPP2 (0.58) | ENPP2FFAR1NPC1RAB9AMGLL | |
| SCHEMBL25233864 | 0.86 | ENPP2 (0.51) | ENPP2FFAR1MAOAMAOBSIRT2 | |
| SCHEMBL31050995 | 0.86 | ENPP2 (0.51) | ENPP2FFAR1MAOAMAOBSIRT2 | |
| SCHEMBL29953375 | 0.86 | LTA4H (0.49) | ENPP2FFAR1LPLLIPG | |
| SCHEMBL22315 | 0.83 | CYP4F2 (0.58) | ENPP2RAB9AMAOAMAOBCYP4F2 | |
| SCHEMBL17912866 | 0.82 | NPC1 (0.60) | FFAR1NPC1RAB9AMAOAMAOB | |
| SCHEMBL2574765 | 0.82 | ENPP2 (0.45) | ENPP2MAOBCYP4F2CYP4A11 | |
| SCHEMBL12663136 | 0.81 | FFAR1 (0.54) | ENPP2FFAR1NPC1RAB9ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761413-B | Carbapenem hydrolysis D-type beta-lactamase inhibitor and preparation method thereof | 明知大学校产学协力团 | 2024-04-12 | — | — | CN | claimed |
| CN-114761413-A | Carbapenem hydrolysis D-type beta-lactamase inhibitor and preparation method thereof | 明知大学校产学协力团 | 2022-07-15 | — | — | CN | claimed |
| CN-114761413-B | Carbapenem hydrolysis D-type beta-lactamase inhibitor and preparation method thereof | 明知大学校产学协力团 | 2024-04-12 | — | — | CN | disclosed |
| CN-114761413-B | Carbapenem hydrolysis D-type beta-lactamase inhibitor and preparation method thereof | 明知大学校产学协力团 | 2024-04-12 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114761413-A | Carbapenem hydrolysis D-type beta-lactamase inhibitor and preparation method thereof | 明知大学校产学协力团 | 2022-07-15 | — | — | CN | disclosed |
| CN-114761413-A | Carbapenem hydrolysis D-type beta-lactamase inhibitor and preparation method thereof | 明知大学校产学协力团 | 2022-07-15 | — | — | CN | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-11058695-B2 | Inhibitor of carbapenem-hydrolyzing class D beta-lactamases | MYONGJI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATION FOUNDATION (KR) | 2021-07-13 | — | — | US | disclosed |
| US-11058695-B2 | Inhibitor of carbapenem-hydrolyzing class D beta-lactamases | MYONGJI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATION FOUNDATION (KR) | 2021-07-13 | — | — | US | disclosed |
| WO-2021091059-A1 | INHIBITOR FOR CARBAPENEM HYDROLYSIS CLASS D BETA-LACTAMASE (CHDL) AND PREPARATION METHOD THEREOF | 명지대학교 산학협력단 | 2021-05-14 | — | — | WO | disclosed |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | ADAMS JULIAN | 2011-09-22 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2073816-B1 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | ENPP2 36/4885FFAR1 32/4885NPC1 570/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | ENPP2 36/4885FFAR1 32/4885NPC1 570/4885 |
| US-11058695-B2 | Inhibitor of carbapenem-hydrolyzing class D beta-lactamases | MGAM, LCT, SI | ENPP2 3406/4885FFAR1 4072/4885NPC1 1667/4885 |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | ENPP2 36/4885FFAR1 32/4885NPC1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.